查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1375994

异位性皮肤炎治疗药物的市场规模、份额和趋势分析报告：按药物类别、给药途径、地区和细分市场预测，2023-2030年

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

异位性皮肤炎治疗药物市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球异位性皮肤炎治疗市场规模预计将达到276.8亿美元。

预计2023年至2030年年复合成长率为8.4%。由于全球异位性皮肤炎盛行率不断上升、认识不断提高以及对治疗的高需求等因素，异位性皮肤炎 (AD) 治疗市场有望迎来成长机会。此外，不断推出创新产品来占领市场，是厂商赢得市场占有率、保持主导地位的关键策略。

越来越多的高效且副作用较少的产品正在研发中，预计将推动市场的发展。例如，预计2020年至2029年间将有11种治疗异位性皮肤炎的新药上市。其中包括以下药物类别：Janus 激酶 (JAK) 抑制剂、磷酸二酯酶-4 (PDE-4) 和白介素-4&-13 (IL-4/13)。这些新药的上市将改善生活质量，为重度和中度AD患者提供治疗选择。

快速通道指定等法规支持预计将加速 AD 的研究和开发。例如，Demira 的 lebrikizumab 获得了快速通道指定。此外，2020年10月，Forte Biosciences, Inc.的药物FB-401获得FDA的快速通道指定。因此，公司对研发的兴趣增加预计将推动市场成长。

增加资金和积极主动的政府配合措施来研究和开发异位性皮肤炎新治疗方法将支持该地区的成长。公共和私人组织之间的合作预计将提高世界各地消费者的意识。例如，2022年6月，大冢製药株式会社（大冢控股株式会社）宣布在日本上市AD治疗药物Moiselt软膏（difamilast）。该药是一种非类固醇外用磷酸二酯酶 4 型抑制剂。

在日本，日本皮肤病学会 (JDA) 制定了 AD 指南。该指南于2020年进行了修订，不仅规定了诊断标准，还规定了治疗方法。例如，用局部皮质类固醇和他克莫司治疗发炎相关的AD。这有利于患者的系统性治疗并提高治疗效果。

特应性皮肤炎治疗药物市场亮点

  • 生物製药生物製药核准数量增加，2022年异位性皮肤炎治疗药物市场以生物製剂为主。
  • 注射给药途径将在 2022 年占据最大份额，并预计在整个预测期内保持其主导地位。
  • 由于领先企业的存在、异位性皮肤炎盛行率的增加以及该地区研究活动的活性化，北美在 2022 年占据了市场主导地位。

目录

第1章调查方法与范围

第2章执行摘要

第3章异位性皮肤炎治疗药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 异位性皮肤炎治疗药物市场的分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章异位性皮肤炎治疗药物：按药物类别估计和趋势分析

  • 异位性皮肤炎治疗药物市场：要点
  • 异位性皮肤炎治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 皮质类固醇
    • 2018年至2030年皮质类固醇市场估计与预测
  • 钙调磷酸酶抑制剂
    • 2018年至2030年钙调神经磷酸酶抑制剂市场估计与预测
  • PDE4抑制剂
    • 2018年至2030年PDE4抑制剂市场预测
  • 生技药品
    • 2018年至2030年生技药品市场估计与预测
  • 其他的
    • 2018 年至 2030 年其他市场估计与预测

第5章异位性皮肤炎治疗药物：按给药途径的估计和趋势分析

  • 异位性皮肤炎治疗药物市场：要点
  • 异位性皮肤炎治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 外用製剂
  • 注射药物
  • 口腔医学

第6章异位性皮肤炎治疗药物市场：区域估计和趋势分析

  • 区域展望
  • 按地区分類的异位性皮肤炎治疗药物市场：关键市场点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Pfizer Inc.
    • Sanofi
    • Regeneron Pharmaceuticals Inc.
    • LEO Pharma Inc
    • Otsuka Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • GALDERMA LABORATORIES, LP
    • Dermira, Inc. (Eli Lilly and Company)
    • Novartis AG
    • Incyte Corporation
Product Code: GVR-2-68038-546-5

Atopic Dermatitis Drugs Market Growth & Trends:

The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 8.4% from 2023 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.'s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights:

  • In 2022, biologics dominated the market owing to their higher demand and rising biologics approvals
  • The injectable route of administration segment held the largest share in 2022 and is likely to maintain its dominance throughout the forecast period
  • North America dominated the market in 2022 due to the presence of leading market players, increased prevalence of atopic dermatitis, and increased research activities within the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Class
    • 1.1.2. Route of Administration
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Atopic Dermatitis Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Atopic Dermatitis Drugs: Drug Class Estimates & Trend Analysis

  • 4.1. Atopic Dermatitis Drugs Market: Key Takeaways
  • 4.2. Atopic Dermatitis Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Corticosteroids
    • 4.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Calcineurin Inhibitors
    • 4.4.1. Calcineurin inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. PDE4 Inhibitors
    • 4.5.1. PDE4 Inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Biologics
    • 4.6.1. Biologics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Drugs: Route of Administration Estimates & Trend Analysis

  • 5.1. Atopic Dermatitis Drugs Market: Key Takeaways
  • 5.2. Atopic Dermatitis Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Topical
    • 5.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Oral
    • 5.5.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Atopic Dermatitis Drugs Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Pfizer Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Sanofi
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Regeneron Pharmaceuticals Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. LEO Pharma Inc
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Otsuka Pharmaceutical Co., Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. AbbVie Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. GALDERMA LABORATORIES, L.P.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Dermira, Inc. (Eli Lilly and Company)
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Novartis AG
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Incyte Corporation
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 4 North America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 U.S. atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7 Canada atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 Canada atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 Europe atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Europe atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Europe atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Germany atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 UK atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 UK atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 France atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 France atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Italy atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Italy atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20 Spain atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Spain atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Sweden atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Sweden atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Norway atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Norway atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 Denmark atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Denmark atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 China atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Japan atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Japan atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 India atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 India atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Thailand atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Thailand atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 South Korea atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 South Korea atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Latin America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Latin America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Latin America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 44 Brazil atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 Brazil atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 Mexico atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Mexico atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Argentina atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Argentina atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 Middle East and Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Middle East and Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 53 South Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 South Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 UAE atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 UAE atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Kuwait atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Kuwait atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Atopic dermatitis drugs: Market outlook
  • Fig. 9 Atopic dermatitis drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Atopic dermatitis drugs market driver impact
  • Fig. 15 Atopic dermatitis drugs market restraint impact
  • Fig. 16 Atopic dermatitis drugs market strategic initiatives analysis
  • Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
  • Fig. 18 Atopic dermatitis drugs market: Drug class outlook and key takeaways
  • Fig. 19 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Calcineurin inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 PDE4 inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Atopic dermatitis drugs market: Route of administration movement analysis
  • Fig. 25 Atopic dermatitis drugs market: Route of administration outlook and key takeaways
  • Fig. 26 Topical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global atopic dermatitis drugs market: Regional movement analysis
  • Fig. 30 Global atopic dermatitis drugs market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)